Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration
Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentr...
Saved in:
Published in | The European respiratory journal Vol. 59; no. 2; p. 2100185 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction (
acidic airway surface liquid (ASL) pH, low bicarbonate (HCO
) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.
We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.
Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO
, normalised mucus recovery to modulator-treated cell levels.
These results indicate that airway dehydration, not acidic pH and/or low [HCO
], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement. |
---|---|
AbstractList | Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction (i.e. acidic airway surface liquid (ASL) pH, low bicarbonate (HCO3 -) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.QUESTIONCystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction (i.e. acidic airway surface liquid (ASL) pH, low bicarbonate (HCO3 -) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.MATERIALS/METHODSWe characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO3 -, normalised mucus recovery to modulator-treated cell levels.RESULTSLoss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO3 -, normalised mucus recovery to modulator-treated cell levels.These results indicate that airway dehydration, not acidic pH and/or low [HCO3 -], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.CONCLUSIONThese results indicate that airway dehydration, not acidic pH and/or low [HCO3 -], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement. Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown. We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties. Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO , normalised mucus recovery to modulator-treated cell levels. These results indicate that airway dehydration, not acidic pH and/or low [HCO ], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement. |
Author | Morton, Lisa C. Shaffer, Kendall M. O'Neal, Wanda K. Morrison, Cameron B. Araba, Kenza C. Quinney, Nancy L. Delion, Martial F. Markovetz, Matthew R. Ehre, Camille Gentzsch, Martina Wykoff, Jason A. Drumm, Mitchell L. Hao, Shuyu Hill, David B. Flen, Alexis L. Liao, Jimmy Kesimer, Mehmet |
AuthorAffiliation | 3 Department of Physics and Astronomy, The University of North Carolina at Chapel Hill 2 Division of Pediatric Pulmonology, The University of North Carolina at Chapel Hill 5 Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill 1 Marsico Lung Institute / CF Center, The University of North Carolina at Chapel Hill 4 Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine |
AuthorAffiliation_xml | – name: 4 Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine – name: 5 Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill – name: 1 Marsico Lung Institute / CF Center, The University of North Carolina at Chapel Hill – name: 3 Department of Physics and Astronomy, The University of North Carolina at Chapel Hill – name: 2 Division of Pediatric Pulmonology, The University of North Carolina at Chapel Hill |
Author_xml | – sequence: 1 givenname: Cameron B. orcidid: 0000-0002-4031-9521 surname: Morrison fullname: Morrison, Cameron B. – sequence: 2 givenname: Kendall M. surname: Shaffer fullname: Shaffer, Kendall M. – sequence: 3 givenname: Kenza C. surname: Araba fullname: Araba, Kenza C. – sequence: 4 givenname: Matthew R. surname: Markovetz fullname: Markovetz, Matthew R. – sequence: 5 givenname: Jason A. surname: Wykoff fullname: Wykoff, Jason A. – sequence: 6 givenname: Nancy L. surname: Quinney fullname: Quinney, Nancy L. – sequence: 7 givenname: Shuyu surname: Hao fullname: Hao, Shuyu – sequence: 8 givenname: Martial F. surname: Delion fullname: Delion, Martial F. – sequence: 9 givenname: Alexis L. surname: Flen fullname: Flen, Alexis L. – sequence: 10 givenname: Lisa C. surname: Morton fullname: Morton, Lisa C. – sequence: 11 givenname: Jimmy surname: Liao fullname: Liao, Jimmy – sequence: 12 givenname: David B. surname: Hill fullname: Hill, David B. – sequence: 13 givenname: Mitchell L. surname: Drumm fullname: Drumm, Mitchell L. – sequence: 14 givenname: Wanda K. surname: O'Neal fullname: O'Neal, Wanda K. – sequence: 15 givenname: Mehmet surname: Kesimer fullname: Kesimer, Mehmet – sequence: 16 givenname: Martina surname: Gentzsch fullname: Gentzsch, Martina – sequence: 17 givenname: Camille surname: Ehre fullname: Ehre, Camille |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34172469$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UU1r3DAQFSWh2Wz6CwpBx16cSpYsS5dAWZoPCBTK3oVWHnVVbGsjyRv231dOsqXJoaeBmffBvHeOTsYwAkKfKbmiVLKvlCnFCGFXhFDZVDWp6Qe0mLfVvD5BC6IIq6hi4gydp_S74ARn9CM6Y5y2NRdqgcI6gskDjBkHh-0hZW-x85sYkk_Y-PhkDthC3yf85PMWr27WP_EQuqk3OcSEI-whJijQDcRoisww2SnhXQw7iNmXy94bvD100WQfxgt06kyf4NPrXKL1zff16q56-HF7v_r2UFkmSK6AsM42RLTcKSvVxkFjhZCidq0zjAtGW24kEVwJZVtGlLAdCCs54a4GwZbo-kV2N20G6Gz5L5pe76IfTDzoYLx-exn9Vv8Key1loySlReDLq0AMjxOkrAef5hzMCGFKum5406i2LkUs0eW_Xn9NjiEXgHoB2JJqiuC09fk5jWLte02JngvVx0L1c6F6LrRw2TvuUf5_rD9bI6TN |
CitedBy_id | crossref_primary_10_1080_17476348_2022_2100350 crossref_primary_10_1093_pnasnexus_pgae390 crossref_primary_10_1016_j_jcf_2024_10_001 crossref_primary_10_1073_pnas_2313089121 crossref_primary_10_1073_pnas_2119680119 crossref_primary_10_1152_ajplung_00390_2022 crossref_primary_10_1186_s12931_024_03029_0 crossref_primary_10_1183_16000617_0068_2024 crossref_primary_10_3389_fphys_2022_884166 crossref_primary_10_2174_011573398X264594231027110541 crossref_primary_10_1126_scitranslmed_abl6328 crossref_primary_10_3390_ijms231911396 crossref_primary_10_3389_fphar_2023_1158207 crossref_primary_10_3390_cells12182208 crossref_primary_10_1002_ppul_26261 crossref_primary_10_1016_j_ejrad_2022_110421 crossref_primary_10_1111_bph_16417 crossref_primary_10_1038_s41598_024_66510_2 crossref_primary_10_1063_5_0187974 crossref_primary_10_3390_ijms24055010 crossref_primary_10_1186_s12931_023_02612_1 crossref_primary_10_7554_eLife_75871 crossref_primary_10_1002_bit_28754 crossref_primary_10_3389_fcimb_2022_969326 crossref_primary_10_1038_s41572_024_00538_6 crossref_primary_10_3390_cells12222618 crossref_primary_10_3389_fphys_2023_1111647 crossref_primary_10_3390_ijms25031933 crossref_primary_10_1007_s00424_024_02937_w crossref_primary_10_1073_pnas_2118126119 crossref_primary_10_1002_advs_202309748 crossref_primary_10_3390_cells11091587 crossref_primary_10_1007_s00018_022_04619_1 crossref_primary_10_3390_ijms231810232 crossref_primary_10_3389_fphar_2023_1293578 crossref_primary_10_1016_j_jcf_2023_05_003 crossref_primary_10_1016_j_coph_2022_102210 crossref_primary_10_1016_j_rmr_2025_01_001 crossref_primary_10_1016_j_heliyon_2023_e15756 crossref_primary_10_1183_13993003_02153_2022 |
Cites_doi | 10.1073/pnas.0904709106 10.1016/j.jcf.2019.05.003 10.1056/NEJMoa043900 10.1007/978-1-61779-120-8_18 10.1126/science.1223012 10.1038/nature11130 10.1126/scitranslmed.3010525 10.1164/rccm.201810-1972OC 10.1164/rccm.201412-2230OC 10.1126/scitranslmed.aav3488 10.1126/science.1255825 10.1016/j.biocel.2014.03.011 10.1002/ppul.24530 10.1016/S0092-8674(00)81724-9 10.1172/JCI73469 10.1016/S0140-6736(08)61162-9 10.1101/cshperspect.a009753 10.1056/NEJMoa1105185 10.1021/acs.biomac.7b00809 10.1016/j.molmed.2007.05.001 10.1152/physrev.00039.2014 10.1101/cshperspect.a009597 10.1056/NEJMoa1701632 10.1183/13993003.01297-2018 10.1172/jci.insight.122695 10.1056/NEJMoa1807119 10.1183/13993003.02652-2017 10.1371/journal.pone.0087681 10.1164/rccm.201404-0670OC 10.1164/rccm.201802-0245OC 10.1038/s41467-017-00532-5 10.1172/JCI83922 |
ContentType | Journal Article |
Copyright | Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. |
Copyright_xml | – notice: Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1183/13993003.00185-2021 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1399-3003 |
ExternalDocumentID | PMC8859811 34172469 10_1183_13993003_00185_2021 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: P01 HL108808 – fundername: NIDDK NIH HHS grantid: P30 DK065988 |
GroupedDBID | --- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AADJU AAFWJ AAYXX AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG ADYFA AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CITATION COF CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 OK1 P2P PQQKQ R0Z RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c360t-e03dc50674f9c89bfe5c66862f7fa3463174a8064969c73096cde6c8404f2e63 |
ISSN | 0903-1936 1399-3003 |
IngestDate | Thu Aug 21 18:38:06 EDT 2025 Fri Jul 11 03:01:06 EDT 2025 Mon Jul 21 06:03:57 EDT 2025 Tue Jul 01 05:42:46 EDT 2025 Thu Apr 24 22:54:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c360t-e03dc50674f9c89bfe5c66862f7fa3463174a8064969c73096cde6c8404f2e63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4031-9521 |
PMID | 34172469 |
PQID | 2545597218 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8859811 proquest_miscellaneous_2545597218 pubmed_primary_34172469 crossref_citationtrail_10_1183_13993003_00185_2021 crossref_primary_10_1183_13993003_00185_2021 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-02-00 20220201 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-00 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The European respiratory journal |
PublicationTitleAlternate | Eur Respir J |
PublicationYear | 2022 |
References | Ramsey (2024102102315534000_59.2.2100185.21) 2016; 112 2024102102315534000_59.2.2100185.18 2024102102315534000_59.2.2100185.16 2024102102315534000_59.2.2100185.15 2024102102315534000_59.2.2100185.14 2024102102315534000_59.2.2100185.13 2024102102315534000_59.2.2100185.12 2024102102315534000_59.2.2100185.11 2024102102315534000_59.2.2100185.33 2024102102315534000_59.2.2100185.10 2024102102315534000_59.2.2100185.32 2024102102315534000_59.2.2100185.31 2024102102315534000_59.2.2100185.30 2024102102315534000_59.2.2100185.9 2024102102315534000_59.2.2100185.7 2024102102315534000_59.2.2100185.8 2024102102315534000_59.2.2100185.5 Donaldson (2024102102315534000_59.2.2100185.25) 2018; 3 2024102102315534000_59.2.2100185.6 2024102102315534000_59.2.2100185.3 2024102102315534000_59.2.2100185.4 2024102102315534000_59.2.2100185.1 2024102102315534000_59.2.2100185.2 2024102102315534000_59.2.2100185.29 2024102102315534000_59.2.2100185.28 Chen (2024102102315534000_59.2.2100185.19) 2019; 200 2024102102315534000_59.2.2100185.27 2024102102315534000_59.2.2100185.26 2024102102315534000_59.2.2100185.24 2024102102315534000_59.2.2100185.23 Hao (2024102102315534000_59.2.2100185.17) 2020; 19 2024102102315534000_59.2.2100185.22 2024102102315534000_59.2.2100185.20 |
References_xml | – ident: 2024102102315534000_59.2.2100185.14 doi: 10.1073/pnas.0904709106 – volume: 19 start-page: 34 year: 2020 ident: 2024102102315534000_59.2.2100185.17 article-title: Inactivation of CFTR by CRISPR/Cas9 alters transcriptional regulation of inflammatory pathways and other networks publication-title: J Cyst Fibros doi: 10.1016/j.jcf.2019.05.003 – ident: 2024102102315534000_59.2.2100185.32 doi: 10.1056/NEJMoa043900 – ident: 2024102102315534000_59.2.2100185.18 doi: 10.1007/978-1-61779-120-8_18 – ident: 2024102102315534000_59.2.2100185.11 doi: 10.1126/science.1223012 – ident: 2024102102315534000_59.2.2100185.24 doi: 10.1038/nature11130 – ident: 2024102102315534000_59.2.2100185.23 doi: 10.1126/scitranslmed.3010525 – volume: 200 start-page: 220 year: 2019 ident: 2024102102315534000_59.2.2100185.19 article-title: XBP1S regulates MUC5B in a promoter variant-dependent pathway in IPF airway epithelia publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201810-1972OC – ident: 2024102102315534000_59.2.2100185.13 doi: 10.1164/rccm.201412-2230OC – ident: 2024102102315534000_59.2.2100185.27 doi: 10.1126/scitranslmed.aav3488 – ident: 2024102102315534000_59.2.2100185.28 doi: 10.1126/science.1255825 – volume: 112 start-page: 54153 year: 2016 ident: 2024102102315534000_59.2.2100185.21 article-title: Mucin agarose gel electrophoresis: Western blotting for high-molecular-weight glycoproteins publication-title: J Vis Exp – ident: 2024102102315534000_59.2.2100185.4 doi: 10.1016/j.biocel.2014.03.011 – ident: 2024102102315534000_59.2.2100185.1 doi: 10.1002/ppul.24530 – ident: 2024102102315534000_59.2.2100185.30 doi: 10.1016/S0092-8674(00)81724-9 – ident: 2024102102315534000_59.2.2100185.10 doi: 10.1172/JCI73469 – ident: 2024102102315534000_59.2.2100185.6 doi: 10.1016/S0140-6736(08)61162-9 – ident: 2024102102315534000_59.2.2100185.2 doi: 10.1101/cshperspect.a009753 – ident: 2024102102315534000_59.2.2100185.15 doi: 10.1056/NEJMoa1105185 – ident: 2024102102315534000_59.2.2100185.8 doi: 10.1021/acs.biomac.7b00809 – ident: 2024102102315534000_59.2.2100185.9 doi: 10.1016/j.molmed.2007.05.001 – ident: 2024102102315534000_59.2.2100185.3 doi: 10.1152/physrev.00039.2014 – ident: 2024102102315534000_59.2.2100185.5 doi: 10.1101/cshperspect.a009597 – ident: 2024102102315534000_59.2.2100185.20 doi: 10.1056/NEJMoa1701632 – ident: 2024102102315534000_59.2.2100185.22 doi: 10.1183/13993003.01297-2018 – volume: 3 start-page: e122695 year: 2018 ident: 2024102102315534000_59.2.2100185.25 article-title: Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR publication-title: JCI Insight doi: 10.1172/jci.insight.122695 – ident: 2024102102315534000_59.2.2100185.16 doi: 10.1056/NEJMoa1807119 – ident: 2024102102315534000_59.2.2100185.33 doi: 10.1183/13993003.02652-2017 – ident: 2024102102315534000_59.2.2100185.12 doi: 10.1371/journal.pone.0087681 – ident: 2024102102315534000_59.2.2100185.31 doi: 10.1164/rccm.201404-0670OC – ident: 2024102102315534000_59.2.2100185.26 doi: 10.1164/rccm.201802-0245OC – ident: 2024102102315534000_59.2.2100185.29 doi: 10.1038/s41467-017-00532-5 – ident: 2024102102315534000_59.2.2100185.7 doi: 10.1172/JCI83922 |
SSID | ssj0016431 |
Score | 2.554577 |
Snippet | Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2100185 |
SubjectTerms | Bicarbonates - metabolism Cystic Fibrosis - metabolism Cystic Fibrosis Transmembrane Conductance Regulator - genetics Cystic Fibrosis Transmembrane Conductance Regulator - metabolism Humans Ion Transport Mucus - metabolism |
Title | Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34172469 https://www.proquest.com/docview/2545597218 https://pubmed.ncbi.nlm.nih.gov/PMC8859811 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkKa9IH5TBshIvIVAmjiO84gmpglUJKBIe4scx1aLaFJlyVD3uL-cu8T50W0g4CWq4sSJ8n217-zv7gh5lUWMpwI1T5Gfucz3IjeWoXYx5jOG6c83DGOH55_4yTf24TQ8nUwuR6qlukrfqIsb40r-B1U4B7hilOw_INt3CifgN-ALR0AYjn-Hca8SR3H4FlMuOwb83wKzjMhV-VNuHVyZtyFsR8eLL1j6Bit2YY0dzN6EEg5HprqEOaty1rWqz1CztUG5NbScr6Sz3GblgN_3gV79Sn452q8fv3gr5m2qHLbikrUugW39Ls_XpcTyLDY-KMNd8vnAQJlK23Ihh8VcDC4qznVThtax1cqt6tEuXoDf6_VCEN0OuGAguYHnBeMR2eYIXw2O8fWBXmDCCbwbb8b9JBECN9po6xH0m3WDPczVkc_aojBX8mt3TbfIbR9cDRwrP34edqLAYpvZbFXwzLc3PPGA7Hd97Bo31zyWq8LbkSWzuEvuWBeEvmv5dI9MdH6f7M-tyOIBKXpa0cLQlla0oxVtaUUbWlGkFUVa0YFWtKMV7WhFG1rRgVYUaEV7Wj0ki-P3i6MT19blcFXAvcrVXpCpEMwcZmIl4tToUHGMNDKRkQHjYJIyKcDWjXmsYAaJuco0V4J5zPiaB4_IXl7k-gmhkfGVTLNQc81YaiRWA8gMWJAm9gVXckr87nsmyuasx9IpP5LGdxVB0uGRNHgkiMeUvO5v2rQpW_58-csOqASGVvx8MtdFfZb44F2EmN1KTMnjFri-ww7xKYl2IO0vwLTtuy35atmkbxcijMVs9vS3fR6Sg-G_8ozsVWWtn4PpW6UvGm7-AptksCs |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+cystic+fibrosis+airway+cells+with+CFTR+modulators+reverses+aberrant+mucus+properties+via+hydration&rft.jtitle=The+European+respiratory+journal&rft.au=Morrison%2C+Cameron+B&rft.au=Shaffer%2C+Kendall+M&rft.au=Araba%2C+Kenza+C&rft.au=Markovetz%2C+Matthew+R&rft.date=2022-02-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=2&rft_id=info:doi/10.1183%2F13993003.00185-2021&rft_id=info%3Apmid%2F34172469&rft.externalDocID=34172469 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon |